Current Report Filing (8-k)
April 05 2021 - 4:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
April 5, 2021
BIO-PATH HOLDINGS,
INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-36333
|
87-0652870
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
4710 Bellaire Boulevard, Suite 210, Bellaire, Texas
|
77401
|
(Address of principal executive offices)
|
(Zip Code)
|
(832) 742-1357
(Registrant’s Telephone Number, Including
Area Code)
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
|
BPTH
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 7.01 Regulation FD Disclosure.
On April 5, 2021, Bio-Path
Holdings, Inc. (the “Company”) issued a press release titled, “Bio-Path Holdings Announces Successful Completion of
Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid
Leukemia.” A copy of such press release is attached hereto as Exhibit 99.1.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
BIO-PATH HOLDINGS, Inc.
|
|
|
|
|
|
|
|
|
|
Dated: April 5, 2021
|
By:
|
/s/ Peter H. Nielsen
|
|
|
|
Peter H. Nielsen
|
|
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Sep 2023 to Sep 2024